Chagas Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Chagas Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major Chagas disease markets are expected to exhibit a CAGR of 3.19% during 2024-2034.

The Chagas disease market has been comprehensively analyzed in IMARC's new report titled "Chagas Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chagas disease, also known as American trypanosomiasis, refers to a neglected tropical disease caused by the parasite Trypanosoma cruzi. It can manifest in two phases: acute and chronic. In the acute phase, which lasts for the initial weeks or months after infection, symptoms may be mild or absent. However, some individuals might experience fever, fatigue, body aches, swollen lymph nodes, and local swelling or redness at the site of the bug bite. In the chronic phase, which can last for years or even decades, the majority of patients remain asymptomatic. However, approximately 30% of infected individuals may develop serious complications, including cardiac abnormalities like cardiomyopathy, heart failure, and arrhythmias, as well as gastrointestinal issues. Diagnosing Chagas disease involves a combination of clinical evaluation, laboratory testing, and medical history assessment. The diagnosis is typically confirmed by diagnostic procedures, such as serological tests, which detect antibodies against Trypanosoma cruzi in the blood. In some cases, direct detection of the parasite through methods like polymerase chain reaction (PCR) or microscopy may be adopted. Additionally, numerous imaging techniques, including electrocardiogram (ECG) and echocardiography, are used to evaluate cardiac involvement.

The increasing cases of contact with infected triatomine bugs, which enter the body through the bite wound or mucosal membranes, such as the conjunctiva or oral cavity, are primarily driving the Chagas disease market. Besides this, the rising prevalence of several associated risk factors, including congenital transmission from an infected mother to her child, blood transfusion or organ transplantation from an infected donor, ingestion of contaminated food or beverages, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of antiparasitic drugs, such as benznidazole and nifurtimox, to kill the parasite as well as reduce the progression of the disease is also bolstering the market growth. Additionally, the emerging popularity of gastrointestinal complication management treatments, including dietary modifications, medications to improve motility, surgical interventions like esophageal or colonic resection, etc., for managing functional disorders related to the esophagus and colon, is further creating a positive outlook for the market. Moreover, the ongoing development of novel drug delivery systems, such as nanoparticles and liposomes, to enhance the bioavailability, targeting, and sustained release of antiparasitic medications is expected to drive the Chagas disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Chagas disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Chagas disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Chagas disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Chagas disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Chagas disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Chagas disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Chagas disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Chagas disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Chagas disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of Chagas disease across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of Chagas disease by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of Chagas disease by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with Chagas disease across the seven major markets?
What is the size of the Chagas disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Chagas disease?
What will be the growth rate of patients across the seven major markets?

Chagas Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Chagas disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Chagas disease market?
What are the key regulatory events related to the Chagas disease market?
What is the structure of clinical trial landscape by status related to the Chagas disease market?
What is the structure of clinical trial landscape by phase related to the Chagas disease market?
What is the structure of clinical trial landscape by route of administration related to the Chagas disease market?